Cell and Gene Manufacturing and Logistics

  1. USP 661.1 Vs 661.2: Key Differences And Compliance 1/9/2026

    USP 661.1 and 661.2 introduce rigorous, risk-based standards for pharmaceutical plastic packaging, emphasizing material characterization, system suitability, and extractables/leachables testing to ensure safety and compliance.

  2. Moving Leukopaks From GTP To GMP Is One Cell Therapy Trend To Watch In '26 1/9/2026

    Cell therapy stumbled in 2025. Solving the variability in starting material quality is critical to stabilizing manufacturing in 2026.

  3. Boost Scalability And Efficiency With Automated Filtration 1/7/2026

    Boost scalability in bioprocessing with automated filtration solutions designed for commercial-scale operations. Achieve reliable performance, low working volumes, and large filtration areas.

  4. Select Your Best Downstream Process Intensification Strategy 1/7/2026

    Intensified and connected processing can cut costs and eliminate bottlenecks in mAb manufacturing. Discover how to identify the most efficient chromatography methods and future-proof your operations.

  5. Boost Process Efficiency With Our New mAb Optimized TFF Cassette 1/7/2026

    Discover how optimized membranes and screen designs enable higher mAb concentrations, improved flux performance, and scalability, while addressing TFF process challenges.

  6. Efficient Purification Of Diverse Single Domain Antibodies 1/7/2026

    Discover how mixed-mode chromatography enables high-yield purification of single-domain antibodies under mild conditions and why these approaches outperform traditional resins.

  7. Filter Sizing For Aqueous Pharmaceutical Solutions 1/7/2026

    Learn how flux, viscosity, and throughput impact filter sizing for aqueous pharmaceutical solutions, as well as gain practical strategies for accurate calculations and scale-up to ensure sterility.

  8. Global Shifts And Strategic Resilience Will Shape CGT In 2026 1/7/2026

    Dr. Miguel Forte, CEO of Kiji Therapeutics and President of ISCT, and Ali Pashazadeh, Founder of Treehill Partners share why CGT developers are now navigating a landscape defined not only by technological innovation but also by geography, regulatory agility, and investment dynamics.

  9. A Deeper Look At Pharma's Structural Supply Chain Vulnerability 12/31/2025

    Fixing limited capacity in pharmaceutical CMC development starts with understanding a complex web of root causes.

  10. What Is ISO 21973 And Why It Matters For Cell And Gene Therapy 12/29/2025

    ISO 21973 establishes global best practices for transporting cell and gene therapies, ensuring quality, safety, and consistency across complex supply chains critical to patient outcomes.